Ann Dermatol.  2009 Feb;21(1):60-62. 10.5021/ad.2009.21.1.60.

Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease

• Park BC
• Lim HJ
• Kim BS
• Lee WJ
• Kim DW
• Lee SJ

• KMID: 2172069
• DOI: http://doi.org/10.5021/ad.2009.21.1.60

Abstract

As more rheumatologists and dermatologists have begun to use biological agents such as TNF-alpha blocker, they have confronted an unexpected complication: psoriasis was paradoxically aggravated or induced by the TNF-alpha blocker. Although it is not a common complication of TNF-alpha blocker, this aggravation may be more common than previously thought. To our knowledge, most reports about TNF-alpha blocker-induced psoriasis have been limited to western countries while only a few cases have been reported in Korea and Japan. In addition, new onset of pustular psoriasis by TNF-alpha blocker has been reported more commonly than worsening of preexisting psoriasis. Now we report a patient whose preexisting psoriasis vulgaris was aggravated repeatedly after using the TNF-alpha blocker, infliximab, to control Crohn's disease, which is a rare rheumatologic disease in Korea.

Keyword

Aggravation; Crohn's disease; Psoriasis; TNF-alpha blocker

MeSH Terms

Antibodies, Monoclonal
Biological Agents
Crohn Disease
Humans
Japan
Korea
Psoriasis
Tumor Necrosis Factor-alpha
Infliximab
Antibodies, Monoclonal
Biological Agents
Tumor Necrosis Factor-alpha

Figure

• 

  Fig. 1 The patient had almost recovered from her aggravated psoriasis with UVB phototherapy and topical steroid before the sixth infliximab treatment.

• 

  Fig. 2 Multiple pruritic erythematous papules and scales developed again and aggravated on her face and extremities after 5 days of the sixth infusion of infliximab.

Reference

1. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003. 48:805–821.

2. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005. 30:713–714.

3. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007. 34:468–472.

4. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum. 2005. 52:1333–1334.

5. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005. 7:R666–R676.

6. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. Korean J Dermatol. 2008. 46:721–723.

7. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007. 143:223–231.

8. Heymann WR. Tumor necrosis factor inhibitor-induced pustular psoriasis? J Am Acad Dermatol. 2007. 56:327–329.

9. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005. 52:2513–2518.